表紙
市場調查報告書

焦點市場分析:中皮腫

Market Spotlight: Mesothelioma

出版商 Datamonitor Healthcare 商品編碼 573553
出版日期 內容資訊 英文 33 Pages
商品交期: 最快1-2個工作天內
價格
焦點市場分析:中皮腫 Market Spotlight: Mesothelioma
出版日期: 2020年08月18日內容資訊: 英文 33 Pages
簡介

2017年,全球45歲及以上人口中的間皮瘤人數估計為18900人,預計到2026年將增至22690人。就各地區別來看,大洋洲是罹患者數最大的地區,拉丁美洲和加勒比地區罹患者數最小。臨床開發中的大多數藥物均處於II期,具有多種靶標。正在開發的大多數藥物都是靜脈注射的,其他藥物包括肌肉注射,口服製劑,腫瘤內藥物,經皮導管/注射劑和皮下製劑。美國是區域臨床試驗的世界領導者,歐盟則以英國,亞洲以日本居首。

本報告提供全球中皮腫的市場調查,彙整疾病的背景·概要,罹患者數的10年預測,開發平台藥物及已上市藥概要,臨床試驗狀況,授權·資產收購等的主要交易趨勢,專利資訊,主要藥物的收益預測等資料。

概要

要點

疾病的背景

治療

  • 外科手術
  • 化療
  • 放射線治療

流行病學

已上市藥物

開發平台藥物

近幾年的發展·分析師的見解

  • Optune
  • SEL-403
  • Tazemetostat

今後的發展

法律規章上的發展

授權·資產取得契約

成功概率

本源專利

商機

臨床試驗環境

  • 贊助商:各狀態
  • 贊助商:不同階段
  • 近幾年的發展

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0178524

Mesothelioma is an aggressive and rare form of cancer which develops in the lining of the heart, lungs, or abdomen. Exposure to asbestos is the primary cause of the disease. The inhalation or swallowing of asbestos leads to an accumulation in the lining of the lungs or the abdomen, causing damage to the tissue. This, in turn, leads to damage to the cells' DNA, and uncontrolled cell growth.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were 30,000 incident cases of mesothelioma in adults aged 40 years and older worldwide, and forecasts that number to increase to 33,900 incident cases by 2028.

Oceania is estimated to have the highest disease incidence rate (9.90 per 100,000 males, and 1.90 per 100,000 females), while Africa has the lowest incidence rate (0.47 per 100,000 males, and 0.30 per 100,000 females).

The approved drugs in the mesothelioma space target thymidylate synthase, the immune system, programmed death-1 receptor/programmed death ligands, and dihydrofolate reductase. All of the approved drugs are administered via the intravenous route.

The majority of industry-sponsored drugs in active clinical development for mesothelioma are in Phase II. Therapies in the mesothelioma space focus on a wide variety of targets. The majority of drugs in development for mesothelioma are administered via the intravenous route, with the remainder being intramuscular, oral, intratumoral, percutaneous catheter/injection, and subcutaneous formulations.

The overall likelihood of approval of a Phase I mesothelioma asset is 5.9%, and the average probability a drug advances from Phase III is 33.3%. Drugs, on average, take 14.9 years from Phase I to approval, compared to 9.4 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for mesothelioma have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.

The US has a substantial lead in the number of mesothelioma clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the mesothelioma space is dominated by completed trials. Eli Lilly has the highest number of completed clinical trials for mesothelioma, with 44 trials. Eli Lilly also leads industry sponsors with the highest overall number of clinical trials for mesothelioma.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Chemotherapy
  • Radiotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Opdivo for Mesothelioma (April 20, 2020)
  • Optune for Mesothelioma (April 2, 2019)

PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of mesothelioma, 2019-28
  • Figure 2: Overview of pipeline drugs for mesothelioma in the US
  • Figure 3: Pipeline drugs for mesothelioma, by company
  • Figure 4: Pipeline drugs for mesothelioma, by drug type
  • Figure 5: Pipeline drugs for mesothelioma, by classification
  • Figure 6: Opdivo for Mesothelioma (April 20, 2020): Phase III - CheckMate 743
  • Figure 7: Probability of success in the mesothelioma pipeline
  • Figure 8: Clinical trials in mesothelioma
  • Figure 9: Top 10 drugs for clinical trials in mesothelioma
  • Figure 10: Top 10 companies for clinical trials in mesothelioma
  • Figure 11: Trial locations in mesothelioma
  • Figure 12: Mesothelioma trials status
  • Figure 13: Mesothelioma trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of mesothelioma, 2019-28
  • Table 2: Incidence rates of mesothelioma, 2019-28
  • Table 3: Marketed drugs for mesothelioma
  • Table 4: Pipeline drugs for mesothelioma in the US
  • Table 5: Opdivo for Mesothelioma (April 20, 2020)
  • Table 6: Optune for Mesothelioma (April 2, 2019)
  • Table 7: Historical global sales, by drug ($m), 2015-19
  • Table 8: Forecasted global sales, by drug ($m), 2020-24